Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 19/20 | 0.42 |
| ▸ | CDK8 | P49336 | 19/20 | 0.42 |
| ▸ | CDK19 | Q9BWU1 | 19/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.38 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6994453 | 1.00 | CCNC (0.42) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7244001 | 0.85 | CCNC (0.57) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7243999 | 0.85 | CCNC (0.57) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7246695 | 0.84 | CCNC (0.48) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL6997511 | 0.78 | CCNC (0.48) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7246930 | 0.77 | CCNC (0.44) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7249485 | 0.76 | CCNC (0.50) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7249813 | 0.72 | CCNC (0.40) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7248292 | 0.69 | CCNC (0.65) | CCNCCDK8CDK19CDK9MAP3K19 | |
| SCHEMBL7246693 | 0.69 | DRD4 (0.67) | CCNCCDK8CDK19CDK9DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1268486-A2 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074823-A2 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | CCNC 2012/4885CDK8 3614/4885CDK19 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.